Canada peptide TikTok claims: what the science actually supports

What did @peptidescanadaedits actually say?

The creator laid out a fairly specific protocol: CJC-1295 without DAC at "100-200 micrograms per injection, typically one to three times per week," administered subcutaneously. They argued it works through GHRH activity, produces "controlled GH pulses" with "less risk of desensitization" compared to the DAC version, and works best stacked with a GHRP. They also recommended four-to-twelve-week cycles with breaks to "preserve receptor sensitivity."

That is a lot of specific claims packed into a short video. Some of them are grounded in real pharmacology. Others are repeated assumptions from bodybuilding forums that have been laundered into mainstream peptide content. The disclaimer at the end, "for education and research purposes only," does not change the fact that this is functional dosing advice delivered to 13,000-plus viewers.

Does the science back this up?

Partially, but the evidence base here is thinner than the confident delivery suggests. CJC-1295 without DAC, also called modified GRF(1-29), does act as a GHRH analogue and does stimulate pulsatile GH release. A key clinical study by Ionescu and Frohman (2006, Journal of Clinical Endocrinology and Metabolism) confirmed that modified GHRH analogues stimulate GH secretion in humans. That part checks out.

The "less risk of desensitization" claim relative to the DAC version has some pharmacological logic behind it. The DAC (Drug Affinity Complex) extension extends the half-life to roughly six to eight days, which does create more continuous GH elevation rather than discrete pulses. Teichman et al. (2006, Journal of Clinical Endocrinology and Metabolism) demonstrated the prolonged half-life of CJC-1295 with DAC and its sustained GH and IGF-1 elevations. The argument that sustained elevation risks more receptor downregulation than pulsatile release is biologically plausible, but direct human trial comparisons between the two forms specifically on desensitization outcomes do not exist in peer-reviewed literature. It is an inference, not a proven fact.

What did they get wrong, or right?

Credit where it is due: the subcutaneous administration recommendation is appropriate for peptides of this class, and pairing a GHRH analogue with a GHRP for synergy is supported by actual research. Alba et al. (2006, Journal of Clinical Endocrinology and Metabolism) showed that GHRH and GHRP combinations produce significantly greater GH release than either alone. The creator gets that right.

What they get wrong, or at least oversimplify, is the dosing confidence. The "100-200 microgram" range comes almost entirely from anecdotal community use, not controlled human trials. No published dose-finding study for CJC-1295 without DAC in healthy adults has established this range as optimal or safe. The creator presents it as settled fact. It is not.

The cycle length recommendation, "four to twelve weeks," is so broad it is nearly meaningless as clinical guidance. And the phrase "preserve receptor sensitivity" sounds precise but is not backed by any published human data on receptor recovery timelines for this compound specifically.

What should you actually know?

CJC-1295 without DAC is an unregulated research compound in most countries, including Canada and the United States. It is not approved by Health Canada or the FDA for any medical indication. That means no standardized manufacturing oversight, no verified purity standards in the commercial supply chain, and no established safety profile from clinical trials in healthy adults.

The mechanistic claims in this video, GHRH stimulation, pulsatile GH release, synergy with GHRPs, are not invented. The pharmacology is real. But pharmacological plausibility is not the same as proven safety and efficacy at the doses and schedules being described. Anyone considering peptide therapy should be working with a licensed clinician who can order baseline labs, monitor IGF-1 levels, and assess individual risk, not reverse-engineering a protocol from a TikTok video.

Growth hormone axis manipulation also carries real risks: insulin resistance, fluid retention, potential effects on cell proliferation, and unknown long-term consequences. These were not mentioned.